Latest news with #Warrant
Yahoo
26-05-2025
- Business
- Yahoo
Finlay Minerals Announces Non-Brokered Private Placement of Flow-Through Shares and Non-Flow-Through Units
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ VANCOUVER, BC, May 26, 2025 /CNW/ - Finlay Minerals Ltd. (TSXV: FYL) (OTCQB: FYMNF) ("Finlay" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement (the "Private Placement") consisting of the issuance of any combination of: (i) common shares of the Company to be issued on a flow-through basis under the Income Tax Act (Canada) (each, a "FT Share") at a price of $0.11 per FT Share, and (ii) non-flow-through units of the Company (each, a "NFT Unit") at a price of $0.10 per NFT Unit, for aggregate gross proceeds to the Company of up to $1,000,000. The Private Placement is subject to a minimum offering amount of $500,000, to be raised through any combination of FT Shares and NFT Units. Each NFT Unit will be comprised of one non-flow-through common share of the Company (each, a "NFT Share") and one non-flow-through common share purchase warrant (a "Warrant"). Each Warrant will be exercisable by the holder thereof to acquire one NFT Share at an exercise price of $0.20 per NFT Share for a period of two years from the date of issuance of the Warrant (the "Warrant Expiry Date"), subject to acceleration. The Warrant Expiry Date may, at the Company's sole discretion, be accelerated if at any time following the Closing Date (as defined herein), the common shares of the Company trade at a daily volume-weighted average trading price above $0.30 per common share for a period of 30 consecutive trading days on the TSX Venture Exchange (the "TSXV") or on such other stock exchange where the majority of the trading occurs (the "Trading Target") and the Company provides notice to the Warrant holders by way of press release announcing that such Trading Target has been achieved, provided that the accelerated expiry date of the Warrants falls on the earlier of (unless exercised by the holder prior to such date) (the "Accelerated Expiry Date"): (i) the 30th day after the Company provides notice to the Warrant holders of its intention to accelerate the Warrant Expiry Date; and (ii) the Warrant Expiry Date. The failure of the Company to give notice in respect of a Trading Target will not preclude the Company from giving notice of any subsequent Trading Target. All Warrants that remain unexercised following the Accelerated Expiry Date shall immediately expire and all rights of holders of such Warrants shall be terminated without any compensation to such holders. The Company intends to use the gross proceeds of the Private Placement for exploration of the Company's SAY, JJB and Silver Hope properties, and for general working capital purposes. The Company will use the gross proceeds from the issuance of FT Shares to incur "Canadian exploration expenses" and qualify as "flow-through mining expenditures", as such terms are defined in the Income Tax Act (Canada). Subject to compliance with applicable regulatory requirements, the Private Placement is being conducted pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions and in reliance on the Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption. The securities issued to purchasers in the Private Placement will not be subject to a hold period under applicable Canadian securities laws. There is an offering document related to the Private Placement that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. The closing of the Private Placement is expected to occur on or about June 9, 2025 (the "Closing Date"). The closing of the Private Placement is subject to certain closing conditions, including the approval of the TSXV. The Company may pay finder's fees in cash and securities to certain arm's length finders engaged in connection with the Private Placement, subject to the approval of the TSXV. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements thereunder. About Finlay Minerals Ltd. Finlay is a TSXV company focused on exploration for base and precious metal deposits through the advancement of its ATTY, PIL, JJB, SAY and Silver Hope Properties; these properties host copper-gold porphyry and gold-silver epithermal targets within different porphyry districts of northern and central BC. Each property is located in areas of recent development and porphyry discoveries with the advantage of hosting the potential for new discoveries. Finlay trades under the symbol "FYL" on the TSXV and under the symbol "FYMNF" on the OTCQB. For further information and details, please visit the Company's website at On behalf of the Board of Directors, Robert F. Brown,Executive Chairman of the Board & Director Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release includes certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as "expect", "plan", "anticipate", "project", "target", "potential", "schedule", "forecast", "budget", "estimate", "intend" or "believe" and similar expressions or their negative connotations, or that events or conditions "will", "would", "may", "could", "should" or "might" occur. All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Forward-looking statements in this news release include statements regarding, among others, the terms and completion of the Private Placement, raising the minimum and maximum amounts of the Private Placement, the payment of finder's fees and issuance of finder's securities, the anticipated closing date and the planned use of proceeds for the Private Placement. Although Finlay believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include the ability to obtain regulatory approval for the Private Placement, the state of equity markets in Canada and other jurisdictions, market prices, exploration successes, and continued availability of capital and financing and general economic, market or business conditions. These forward-looking statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions, the timing and receipt of regulatory and governmental approvals, the ability of Finlay and other parties to satisfy stock exchange and other regulatory requirements in a timely manner, the availability of financing for Finlay's proposed transactions and programs on reasonable terms, and the ability of third-party service providers to deliver services in a timely manner. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements, and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Finlay does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future or otherwise, except as required by applicable law. SOURCE Finlay Minerals Ltd. View original content to download multimedia:
Yahoo
26-05-2025
- Business
- Yahoo
Finlay Minerals Announces Non-Brokered Private Placement of Flow-Through Shares and Non-Flow-Through Units
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ VANCOUVER, BC, May 26, 2025 /CNW/ - Finlay Minerals Ltd. (TSXV: FYL) (OTCQB: FYMNF) ("Finlay" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement (the "Private Placement") consisting of the issuance of any combination of: (i) common shares of the Company to be issued on a flow-through basis under the Income Tax Act (Canada) (each, a "FT Share") at a price of $0.11 per FT Share, and (ii) non-flow-through units of the Company (each, a "NFT Unit") at a price of $0.10 per NFT Unit, for aggregate gross proceeds to the Company of up to $1,000,000. The Private Placement is subject to a minimum offering amount of $500,000, to be raised through any combination of FT Shares and NFT Units. Each NFT Unit will be comprised of one non-flow-through common share of the Company (each, a "NFT Share") and one non-flow-through common share purchase warrant (a "Warrant"). Each Warrant will be exercisable by the holder thereof to acquire one NFT Share at an exercise price of $0.20 per NFT Share for a period of two years from the date of issuance of the Warrant (the "Warrant Expiry Date"), subject to acceleration. The Warrant Expiry Date may, at the Company's sole discretion, be accelerated if at any time following the Closing Date (as defined herein), the common shares of the Company trade at a daily volume-weighted average trading price above $0.30 per common share for a period of 30 consecutive trading days on the TSX Venture Exchange (the "TSXV") or on such other stock exchange where the majority of the trading occurs (the "Trading Target") and the Company provides notice to the Warrant holders by way of press release announcing that such Trading Target has been achieved, provided that the accelerated expiry date of the Warrants falls on the earlier of (unless exercised by the holder prior to such date) (the "Accelerated Expiry Date"): (i) the 30th day after the Company provides notice to the Warrant holders of its intention to accelerate the Warrant Expiry Date; and (ii) the Warrant Expiry Date. The failure of the Company to give notice in respect of a Trading Target will not preclude the Company from giving notice of any subsequent Trading Target. All Warrants that remain unexercised following the Accelerated Expiry Date shall immediately expire and all rights of holders of such Warrants shall be terminated without any compensation to such holders. The Company intends to use the gross proceeds of the Private Placement for exploration of the Company's SAY, JJB and Silver Hope properties, and for general working capital purposes. The Company will use the gross proceeds from the issuance of FT Shares to incur "Canadian exploration expenses" and qualify as "flow-through mining expenditures", as such terms are defined in the Income Tax Act (Canada). Subject to compliance with applicable regulatory requirements, the Private Placement is being conducted pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions and in reliance on the Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption. The securities issued to purchasers in the Private Placement will not be subject to a hold period under applicable Canadian securities laws. There is an offering document related to the Private Placement that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. The closing of the Private Placement is expected to occur on or about June 9, 2025 (the "Closing Date"). The closing of the Private Placement is subject to certain closing conditions, including the approval of the TSXV. The Company may pay finder's fees in cash and securities to certain arm's length finders engaged in connection with the Private Placement, subject to the approval of the TSXV. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements thereunder. About Finlay Minerals Ltd. Finlay is a TSXV company focused on exploration for base and precious metal deposits through the advancement of its ATTY, PIL, JJB, SAY and Silver Hope Properties; these properties host copper-gold porphyry and gold-silver epithermal targets within different porphyry districts of northern and central BC. Each property is located in areas of recent development and porphyry discoveries with the advantage of hosting the potential for new discoveries. Finlay trades under the symbol "FYL" on the TSXV and under the symbol "FYMNF" on the OTCQB. For further information and details, please visit the Company's website at On behalf of the Board of Directors, Robert F. Brown,Executive Chairman of the Board & Director Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release includes certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as "expect", "plan", "anticipate", "project", "target", "potential", "schedule", "forecast", "budget", "estimate", "intend" or "believe" and similar expressions or their negative connotations, or that events or conditions "will", "would", "may", "could", "should" or "might" occur. All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Forward-looking statements in this news release include statements regarding, among others, the terms and completion of the Private Placement, raising the minimum and maximum amounts of the Private Placement, the payment of finder's fees and issuance of finder's securities, the anticipated closing date and the planned use of proceeds for the Private Placement. Although Finlay believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include the ability to obtain regulatory approval for the Private Placement, the state of equity markets in Canada and other jurisdictions, market prices, exploration successes, and continued availability of capital and financing and general economic, market or business conditions. These forward-looking statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions, the timing and receipt of regulatory and governmental approvals, the ability of Finlay and other parties to satisfy stock exchange and other regulatory requirements in a timely manner, the availability of financing for Finlay's proposed transactions and programs on reasonable terms, and the ability of third-party service providers to deliver services in a timely manner. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements, and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Finlay does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future or otherwise, except as required by applicable law. SOURCE Finlay Minerals Ltd. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-05-2025
- Business
- Yahoo
Alligator Bioscience Announces that 85% of the Warrant Programme TO 12 has Been Secured and that the Outstanding Loan has Been Renegotiated
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. LUND, SWEDEN / / May 9, 2025 / Alligator Bioscience (STO:ATORX)("Alligator Bioscience" or the "Company") hereby announces that the Company has received undertakings corresponding to 85 per cent of the outstanding warrants series TO 12 ("TO 12") (the "Warrant Programme"). The Company has received subscription undertakings from the Company's Chairman of the Board of Directors, CEO and CFO as well as several larger and smaller holders of TO 12, including Roxette Photo SA, amounting in total to approximately SEK 16.2 million and corresponding to approximately 22.4 per cent of the Warrant Programme (the "Subscription Undertakings"). In addition to the Subscription Undertakings, the Company has received guarantee undertakings from existing holders of TO 12 and external investors in the form of so-called top and bottom guarantees amounting to approximately SEK 45.4 million, corresponding to approximately 62.7 per cent of the Warrant Programme (the "Guarantee Undertakings"). The Company has also received a subscription intention amounting up to SEK 3 million from one of the Company's larger shareholders, where such intention is not included in the guarantee structure. The Guarantee Undertakings will be utilized in case the subscription of ordinary shares in the Warrant Programme is below approximately 85 per cent. The exercise period for TO 12 runs up to and including 19 May 2025. The last day of trading in TO 12 is 15 May 2025. In connection with the above, Alligator Bioscience has also renegotiated the outstanding loan from Fenja Capital II A/S ("Fenja Capital"), which originally was raised in June 2024 and subsequently renegotiated in December 2024. Søren Bregenholt, CEO of Alligator Bioscience, comments: "Securing this Warrant Programme on reasonable terms will reduce overall company risk and enables us to move forward with our ambition of bringing mitazalimab to the market together with a partner. In collaboration with our global transaction advisor, we are advancing our discussions with potential strategic partners for mitazalimab, including a number of global pharma and commercial-stage biotech companies. These dialogues have intensified following the announcement of 24-month survival data, further dose validation, and regulatory alignment with the FDA. We are proceeding with confidence and determination toward our goal of securing a partnership and subsequent Phase 3 initiation." Alligator Bioscience carried out a rights issue of units during December 2024 - February 2025 (the "Rights Issue"). Each unit issued in the Rights Issue consisted of ten (10) ordinary shares, ten (10) warrants series TO 12 and five (5) warrants series TO 13. A total of 16,145,769,260 TO 12 were issued in the Rights Issue, including warrants issued as guarantee compensation. In addition, in connection with the Rights Issue and a renegotiation of an outstanding loan, the Board of Directors resolved on a directed issue of 3,500,000,000 TO 12 in total in February 2025. The total number of outstanding TO 12 thus amounts to 19,645,769,260. As a result of the reverse share split that was carried out in the Company in the spring of 2025, a recalculation of the subscription price and the number of ordinary shares that each TO 12 entitles to subscription of has been carried out. After the recalculation, each warrant entitles to subscription of 0.001 ordinary shares. As subscription cannot be made for part of an ordinary share, 1,000 TO 12 will be required to subscribe for one (1) new ordinary share in the Company. In accordance with the press release announced by the Company on 28 April 2025, the subscription price per ordinary share for TO 12 has been set at SEK 3.68. The exercise period for TO 12 runs up to and including 19 May 2025. Exercise should take place well before 19 May 2025 as different nominees have different processing times and application deadlines. The last day of trading in TO 12 is 15 May 2025. Subscription and Guarantee UndertakingsThe Company has received Subscription Undertakings from the Company's Chairman of the Board of Directors, CEO and CFO as well as several larger and smaller holders of TO 12, including Roxette Photo SA, amounting in total to approximately SEK 16.2 million and corresponding to approximately 22.4 per cent of the Warrant Programme. In addition to the Subscription Undertakings, the Company has received Guarantee Undertakings from existing holders of TO 12 and external investors amounting to approximately SEK 45.4 million, corresponding to approximately 62.7 per cent of the Warrant Programme. The Guarantee Undertakings are composed partly of so-called top guarantees of approximately SEK 10.9 million in total and partly of so-called bottom guarantees of approximately SEK 34.5 million in total. According to the agreements, for the top guarantee as well as for the bottom guarantees, cash compensation is paid with 10 per cent of the guaranteed amount, corresponding to a total of approximately SEK 4.5 million, or 12 per cent of the guaranteed amount in the form of newly issued ordinary shares in the Company, at the subscription price of SEK 3.68 per ordinary share. The Guarantee Undertakings are not secured by way of a first priority transaction, bank guarantee, pledge or similar and will be utilized in case the subscription of ordinary shares in the Warrant Programme is below approximately 85 per cent. The Company has also received a subscription intention amounting up to SEK 3 million from one of the Company's larger shareholders, where such intention is not included in the guarantee structure. Any subscription of ordinary shares under the Guarantee Undertakings will in practice be made through subscription in a directed share issue, resolved by the Board of Directors based on the authorization from the annual general meeting on 7 May 2025 or subject to approval by a subsequent extraordinary general meeting to be convened for such purpose, after the exercise period for TO 12 has ended (the "Directed Share Issue"). The fulfilment of the Guarantee Undertakings is thus conditional upon approval by the extraordinary general meeting, if such general meeting is needed to be convened. Any subscription in the Directed Share Issue will be made at the same subscription price as for the exercise of TO 12, i.e. SEK 3.68 per ordinary share, and may thus comprise a maximum of 12,324,631 ordinary shares in the Company, corresponding to issue proceeds of approximately SEK 45.4 million in total. The outcome of the exercise of TO 12 and the amount of Guarantee Undertakings utilized will be announced through a separate press release by the Company on or around 21 May 2025. Renegotiation of outstanding loanIn connection with the Rights Issue, as announced in the Company's press release from 2 December 2024, the Company renegotiated the outstanding loan and convertibles from Fenja Capital, which were originally raised in June 2024, with a new loan being arranged thereafter (the "New Loan").For further information on the New Loan, please refer to the Company's press releases from 2 December 2024 and 14 February 2025. As part of the undertakings relating to the Warrant Programme, Alligator Bioscience has renegotiated the repayment structure in connection with the exercise of TO 12 under the New Loan (the "Loan Amendment"). Pursuant to the Loan Amendment, the Company shall, in connection with the exercise of TO 12, repay a nominal amount of approximately SEK 12.2 million of the New Loan to Fenja Capital (which may be repaid in cash, or by way of set-off subject to Fenja Capital being allotted shares under its top guarantee commitment). In connection with the Loan Amendment, an amendment fee of approximately SEK 1.1 million will be payable in cash and a repayment fee of approximately SEK 0.4 million will be added to the New Loan. After the repayment and the addition of the repayment fee as per the foregoing, approximately SEK 23.1 million will thus be outstanding under the New Loan. The Loan Amendment also stipulates that the maturity date for the New Loan shall be changed from 30 November 2025 to 30 September 2025 and that the New Loan shall be subject to an interest rate of 1.25 per cent per each beginning 30-day period from the repayment. Interest accrued for the period until 30 June 2025 shall be added to the New Loan as of 30 June 2025 and be payable on the maturity date. Interest accrued for the period after 30 June 2025 shall become due at the maturity date. In addition, the previous requirement that the Company shall repay an amount of SEK 5 million if the New Loan at the end of a calendar quarter, for the first time at the end of the second quarter of 2025, exceeds 10 per cent of the Company's market capitalization, has been removed in connection with the Loan Amendment. Finally, for future repayments of the New Loan, i.e. for the amount outstanding after the repayment in connection with the exercise of TO 12, the repayment fee shall amount to 5 per cent instead of 3 per cent. Otherwise, the original terms and conditions of the New Loan shall continue to apply (including the repayment structure in connection with the exercise of warrants series TO 13). AdvisersVator Securities AB acts as Sole Global Coordinator and bookrunner in connection with the Rights Issue and Van Lanschot Kempen N.V. acts as financial adviser to Alligator Bioscience in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Alligator Bioscience in connection with the Rights Issue. Vator Securities AB acts as the issuing agent in connection with the Rights Issue. For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 This information is information that Alligator Bioscience is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-05-09 16:05 CEST. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit IMPORTANT INFORMATION The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Alligator Bioscience. The invitation to the persons concerned to subscribe for units consisting of ordinary shares, warrants series TO 12 and warrants series TO 13 in Alligator Bioscience has only been made through the prospectus published by Alligator Bioscience on 24 January 2025. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company's website, Since Alligator Bioscience is considered to conduct protection-worthy activities according to the Swedish Screening of Foreign Direct Investments Act (Sw. lag (2023:560) om granskning av utländska direktinvesteringar), the exercise of warrants for subscription of ordinary shares may require review by the Inspectorate of Strategic Products (ISP). More information about this can be found on the Company's website, Attachments Alligator Bioscience announces that 85% of the warrant programme TO 12 has been secured and that the outstanding loan has been renegotiated SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire
Yahoo
13-02-2025
- Yahoo
‘No ICE movement': Meck County Sheriff addresses Honduras national facing violent charges being released after 5 days
MECKLENBURG COUNTY, N.C. (QUEEN CITY NEWS) — Sheriff Garry McFadden came forward with information on Thursday regarding a Honduras national who was arrested in January for violent crimes, held for five days, and ultimately released from custody. McFadden issued a statement on Thursday, claiming recent reports on U.S. Immigration and Customs Enforcement have been 'incorrect and misleading.' According to jail records, the suspect in question, Jose Napoleon-Serrano, 40, was taken into custody on Jan. 12, 2025, and charged with assault on a female, misdemeanor crime of domestic violence, and assault with a deadly weapon inflicting serious injury. On Jan. 17, 2025, Napoleon-Serrano posted his $5,000 bond and he was released that afternoon. According to McFadden, the Mecklenburg County Sheriff's Office followed the state law by holding him for 48 hours, per a court order. McFadden provided a timeline of events leading up to Napoleon-Serrano's release. According to the sheriff's office, Serrano was arrested by CMPD on Jan. 12 at 5:35 a.m. Mecklenburg County deputies reportedly determined he was a Honduran national during the intake process. McFadden said that same day at 6:09 a.m., the sheriff's office notified ICE, 'with no response the entire day.' He said more than 24 hours later, on Jan. 13, at 11:18 a.m., the sheriff's office received the ICE Detainer-Administrative Warrant. McFadden said a 48-hour hold was signed and issued by a state magistrate. Then on Jan. 15, at 11:18 a.m., he said the court order on Napoleon-Serrano was lifted but he remained in custody at the Detention Center on his initial state charges with a $5,000 secured bond. On Jan. 17, at 12:14 p.m., more than 48 hours later, McFadden said Napoleon-Serrano's $5,000 bond was posted for his release. A magistrate issued a signed court order for his release. McFadden said Napoleon-Serrano was held for five days with no ICE movement. Below is part of McFadden's statement to Charlotte-area news organizations: MCSO received zero correspondence from ICE after they sent the detainer on January 13th. ICE was aware of Mr. Serrano's status between January 12th-17th as they are privy to our various tracking systems. ICE is more than welcome to pick up the phone – we will always remain transparent about a person's release, but nowhere in House Bill 10 does it mandate local sheriffs to notify ICE of an individual's release. ICE is also aware that Mr. Serrano had been deported twice before. If they believed he posed a threat to public safety, I question why ICE didn't charge Mr. Serrano with federal offenses under 8 USC 1325 (Improper Entry by Alien) and 8 USC 1326 (Re-entry of Deported Alien), instead of putting the burden on local sheriffs. This is why I continue to emphasize the importance of open discussions with ICE — because simply deporting individuals is not an effective solution and does not make our communities safer. So again, I have followed the law. I have my responsibilities as Sheriff of Mecklenburg County, and ICE has theirs. However, ICE cannot expect me to operate outside the scope of the law as my predecessors have done. I am not an ICE officer. I am the Sheriff, and my priority is serving and protecting my community while always upholding the law. Sheriff Garry McFaddenCopyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
05-02-2025
- Entertainment
- Yahoo
Bret Michaels, Warrant to perform at Pearl Day concert
PEARL, Miss. (WJTV) – Bret Michaels will bring his Parti-Gras Tour to Trustmark Park for Pearl Day. The free concert event will will kick off with Warrant at 7:00 p.m. on Saturday, April 26, 2025, who will bring their iconic hits like 'Heaven,' 'Cherry Pie,' and 'Uncle Tom's Cabin' to the stage. Gavin Adcock to perform at Brandon Amphitheater Michaels will take the stage at 8:45 p.m. His hits include 'Every Rose Has Its Thorn,' 'Nothin' But A Good Time,' 'Talk Dirty to Me,' and 'Your Mama Don't Dance.' 'What better way to celebrate Pearl Day having two music icons with us! I look forward to all of the fun at this event!' said Pearl Mayor Jake Windham Attendees are encouraged to bring chairs for the event. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
